ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA

This study sought to determine whether re-irradiation (ReRT) and concurrent bevacizumab (BEV) improves overall survival (OS) compared to BEV alone in recurrent glioblastoma (GBM). Patients (pts) were randomized 1:1 to ReRT (35 Gy/10 fractions) plus BEV (IV 10 mg/kg q2 wks) vs. BEV alone. With 160 pt...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Tsien, Christina, Pugh, Stephanie, Dicker, adam, Raizer, Jeffrey, Matuszak, Martha, Lallana, Enrico, Huang, Jiayi, algan, ozer, Taylor, Nicholas, Portelance, Lorraine, Villano, John, T Hamm, John, S Oh, Kevin, N Ali, Arif, Kim, Michelle, Lindhorst, Scott, Mehta, Minesh
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Adult Clinical Trials - Non-Immunologic
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847814/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.075
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы